Analyst Price Targets — SCTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 10:11 am | — | H.C. Wainwright | $60.00 | $28.44 | TheFly | Scribe Therapeutics initiated with a Buy at H.C. Wainwright |
| August 18, 2026 10:08 am | David Risinger | Leerink Partners | $37.00 | $21.19 | TheFly | Scribe Therapeutics initiated with an Outperform at Leerink |
| August 18, 2026 9:33 am | — | Guggenheim | $50.00 | $21.19 | TheFly | Scribe Therapeutics initiated with a Buy at Guggenheim |
| August 18, 2026 9:04 am | — | Wells Fargo | $60.00 | $21.19 | TheFly | Scribe Therapeutics initiated with an Overweight at Wells Fargo |
Latest News for SCTX
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences: Wells Fargo…
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock,…
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SCTX.
U.S. House Trading
No House trades found for SCTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.